vs
Side-by-side financial comparison of Allot Ltd. (ALLT) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $24.1M, roughly 2.0× Allot Ltd.). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -7.0%, a 2.3% gap on every dollar of revenue. On growth, Allot Ltd. posted the faster year-over-year revenue change (8.5% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $4.0M).
Allot Ltd., formerly Allot Communications, is an Israeli high-tech company that develops telecommunications software. The company is headquartered in Hod Hasharon, Israel.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
ALLT vs IRWD — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.1M | $47.7M |
| Net Profit | $-1.7M | $-2.3M |
| Gross Margin | 72.1% | — |
| Operating Margin | -1.7% | 14.3% |
| Net Margin | -7.0% | -4.8% |
| Revenue YoY | 8.5% | -47.3% |
| Net Profit YoY | 49.6% | -200.9% |
| EPS (diluted) | $-0.04 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $47.7M | ||
| Q3 25 | — | $122.1M | ||
| Q2 25 | $24.1M | $85.2M | ||
| Q1 25 | $23.1M | $41.1M | ||
| Q4 24 | — | $90.5M | ||
| Q3 24 | — | $91.6M | ||
| Q2 24 | $22.2M | $94.4M | ||
| Q1 24 | — | $74.9M |
| Q4 25 | — | $-2.3M | ||
| Q3 25 | — | $40.1M | ||
| Q2 25 | $-1.7M | $23.6M | ||
| Q1 25 | $-332.0K | $-37.4M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $3.6M | ||
| Q2 24 | $-3.4M | $-860.0K | ||
| Q1 24 | — | $-4.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 72.1% | — | ||
| Q1 25 | 69.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 68.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 61.8% | ||
| Q2 25 | -1.7% | 53.2% | ||
| Q1 25 | -3.1% | -70.7% | ||
| Q4 24 | — | 34.8% | ||
| Q3 24 | — | 28.0% | ||
| Q2 24 | -15.2% | 26.5% | ||
| Q1 24 | — | 14.7% |
| Q4 25 | — | -4.8% | ||
| Q3 25 | — | 32.8% | ||
| Q2 25 | -7.0% | 27.7% | ||
| Q1 25 | -1.4% | -90.9% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | -15.1% | -0.9% | ||
| Q1 24 | — | -5.6% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | — | $0.23 | ||
| Q2 25 | $-0.04 | $0.14 | ||
| Q1 25 | $-0.01 | $-0.23 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | $-0.09 | $-0.01 | ||
| Q1 24 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.1M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $99.7M | $-261.8M |
| Total Assets | $154.1M | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $215.5M | ||
| Q3 25 | — | $140.4M | ||
| Q2 25 | $60.1M | $92.9M | ||
| Q1 25 | $10.1M | $108.5M | ||
| Q4 24 | — | $88.6M | ||
| Q3 24 | — | $88.2M | ||
| Q2 24 | $15.9M | $105.5M | ||
| Q1 24 | — | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | — | $-261.8M | ||
| Q3 25 | — | $-264.2M | ||
| Q2 25 | $99.7M | $-308.2M | ||
| Q1 25 | $50.0M | $-334.1M | ||
| Q4 24 | — | $-301.3M | ||
| Q3 24 | — | $-311.3M | ||
| Q2 24 | $46.7M | $-321.7M | ||
| Q1 24 | — | $-330.5M |
| Q4 25 | — | $396.9M | ||
| Q3 25 | — | $396.1M | ||
| Q2 25 | $154.1M | $342.9M | ||
| Q1 25 | $140.3M | $327.2M | ||
| Q4 24 | — | $350.9M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | $132.5M | $395.6M | ||
| Q1 24 | — | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.4M | $74.6M |
| Free Cash FlowOCF − Capex | $4.0M | $74.6M |
| FCF MarginFCF / Revenue | 16.5% | 156.3% |
| Capex IntensityCapex / Revenue | 1.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-6.0M | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | $4.4M | $-15.1M | ||
| Q1 25 | $1.7M | $20.0M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | $1.2M | $33.5M | ||
| Q1 24 | — | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | $4.0M | $-15.1M | ||
| Q1 25 | $1.4M | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | $217.0K | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | 16.5% | -17.7% | ||
| Q1 25 | 6.1% | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | 1.0% | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 1.7% | 0.0% | ||
| Q1 25 | 1.2% | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | 4.3% | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
